Market Place
Company
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
X
Active Filter(s):
Details:
Carmell Therapeutics is in early preclinical testing of BHA product as an orthobiolgoic to determine the capability of BHA to act as an enhancer to existing bone graft substitutes as well as a stand-alone new alternative to bone graft substitute products.
Lead Product(s): Allogeneic Plasma-based Biomaterial,Calcium Phosphate
Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: BHA
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Alpha Healthcare Acquisition Corp.
Deal Size: $154.0 million Upfront Cash: Undisclosed
Deal Type: Merger January 04, 2023
Details:
The Fast Track status offers the company benefits in improving and accelerating the company's trial on Bone Healing Accelerant in open tibia fractures to the target of a Biologic License Application.
Lead Product(s): Calcium Phosphate,Blood-derived component
Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2020
Details:
Carmell to begin enrolling in pivotal clinical program for first-of-its-kind Plasma-based Bioactive Material product used in long-bone fractures as an adjunctive treatment.
Lead Product(s): Calcium Phosphate
Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 07, 2020
